PomegraVir Biotechnology Stock Jumps 15% After Phase 3 Trial Win
Why is Vir Biotechnology stock up today?
Vir Biotechnology (VIR) stock rose about 15% in premarket trading on Monday to $14.07 after its hepatitis delta drug combination met the main goal of a Phase 3 trial.
Key numbers
| VIR premarket price | $14.07+15.23% from $12.21 close; Investing.com cites +22% later |
|---|---|
| Primary endpoint response | 44%vs 0% delayed treatment |
| Undetectable virus at Week 48 | 79%vs 0% delayed treatment |
| Patients enrolled | 124randomized 2:1 |
| VIR gain this year | ~102%before Monday's move (per [3]) |
| Cash and investments | $901.3Mas of Sept. 30 |
What happened
Vir Biotechnology (VIR) stock rose about 15% in premarket trading on Monday to $14.07 after its hepatitis delta drug combination met the main goal of a Phase 3 trial. The trial, called ECLIPSE 1, tested two monthly injections, elebsiran and tobevibart, in 124 adults with hepatitis delta, a serious liver infection. In treated patients, 44% had no detectable virus and normal liver enzymes at Week 48, versus 0% of untreated patients at Week 12. Vir plans to ask the US FDA for approval in mid-2027.
Why it matters
Vir Biotechnology now has strong late-stage data for a possible new hepatitis delta treatment, a disease with very few options. Only one drug, Gilead's daily-injection Hepcludex, is approved in the US. Vir's treatment would be a monthly injection, which could be easier for patients. Two more trials due in early 2027 will still need to confirm the picture.
Who this affects
- MarketbullishMedium impact
- Vir shareholders gain; biotech investors see a rare late-stage win.
- CompanybullishHigh impact
- Vir moves closer to its first FDA filing, planned mid-2027.
- CompetitorsmixedMedium impact
- Gilead's Hepcludex may face a monthly-dosing rival.
- IndustrybullishLow impact
- Patients with hepatitis delta could gain a new treatment choice.
Vir Biotechnology vs Gilead
How we got here
FDA grants Gilead's Hepcludex first US approval for hepatitis delta
Vir reports Q3 results, $901.3M cash, ECLIPSE 1 data due in Q4
Vir announces ECLIPSE 1 met its primary endpoint
Shares rise about 15% premarket from $12.21 Friday close
What to watch
- ECLIPSE 2 and ECLIPSE 3 trial results, including comparison with Gilead's drugQ1 2027
- Vir's planned FDA approval filing for elebsiran and tobevibartmid-2027
Educational content only. Not investment advice.
More briefsAll briefs →
Greenfire Stock Jumps 25% After Strathcona Takeover Deal
Greenfire Resources (GFR) is being bought for up to C$2.9B, with a C$11 cash option at a 39% premium.
Trump Calls Deportations 'Too Tough,' Vows Pardons, Firings
Stephen Miller replaces Susie Wiles as chief of staff days after Democrats won the House and Senate.
Ukraine Peace Talks Open Nov 10 in Abu Dhabi as Europe Joins
US-mediated Russia-Ukraine talks run two days in Abu Dhabi, with EU, French, German and UK officials present.